The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8(+) T cells
- Author(s)
- Mueller, SN; Jones, CM; Chen, WS; Kawaoka, Y; Castrucci, MR; Heath, WR; Carbone, FR;
- Details
- Publication Year 2003-02,Volume 77,Issue #4,Page 2445-2451
- Journal Title
- JOURNAL OF VIROLOGY
- Publication Type
- Journal Article
- Abstract
- The immune response to cutaneous herpes simplex virus type I (HSV-1) infection begins with remarkable rapidity. Activation of specific cytotoxic T lymphocytes (CTL) begins within hours of infection, even though the response within the draining lymph nodes peaks nearly 5 days later. HSV gene products are classified into three main groups, alpha, beta, and gamma, based on their kinetics and requirements for expression. In C57BL/6 mice, the immunodominant epitope from HSV is derived from glycoprotein B (gB(498-505)). While gB is considered a gamma or "late" gene product, previous reports have indicated that some level of gene expression may occur soon after infection. Using brefeldin A as a specific inhibitor of viral antigen presentation to major histocompatibility complex class I-restricted CTL, we have formally addressed the timing of gB peptide expression in an immunologically relevant manner following infection. Presentation of gB peptide detected by T-cell activation was first observed within 2 h of infection. Comparison with another viral epitope expressed early during infection, HSV-1 ribonucleotide reductase, demonstrated that gB is presented with the same kinetics as this classical early-gene product. Moreover, this rapidity of gB expression was further illustrated via rapid priming of naive transgenic CD8(+) T cells in vivo after HSV-1 infection of mice. These results establish that gB is expressed rapidly following HSV-1 infection, at levels capable of effectively stimulating CD8(+) T cells.
- Publisher
- AMER SOC MICROBIOLOGY
- Keywords
- MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC LYMPHOCYTES-T; DENDRITIC CELLS; ENDOPLASMIC-RETICULUM; SYNTHETIC PEPTIDES; INFLUENZA-VIRUS; IN-VIVO; TYPE-1; INFECTION; TRANSPORT
- Publisher's Version
- https://doi.org/10.1128/JVI.77.4.2445-2451.2003
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2003-02-01 12:00:00